<?xml version="1.0" encoding="UTF-8"?>
<p id="par0050">ARDS is a clinical entity characterized by progressive bilateral pulmonary infiltrates that cannot be fully explained by cardiac disease or volume overload. Despite advances on the understanding of this condition, mortality remains significant [
 <xref rid="bib0060" ref-type="bibr">12</xref>]. Management involves lung-protective ventilation, prone positioning, corticosteroids, paralytics and ECMO. The use of corticosteroids is controversial, with data showing that high dose of steroids fails to improve mortality and might cause harm [
 <xref rid="bib0065" ref-type="bibr">13</xref>,
 <xref rid="bib0070" ref-type="bibr">14</xref>]. On the other hand, the CESAR trial showed improved survival on ECMO compared to conservative management with medium duration of cannulation of 9 days [
 <xref rid="bib0075" ref-type="bibr">15</xref>]. Our patient was started on high dose methylprednisolone along with ECMO support, given the improvement on her respiratory status she was decannulated after 4 days.
</p>
